Development and validation of functional cell therapies for Huntington's and Parkinson's diseases

亨廷顿病和帕金森病功能性细胞疗法的开发和验证

• 批准号: G0500794/1
• 负责人: Stephen Dunnett
• 金额: $ 206.26万
• 依托单位: CARDIFF UNIVERSITY
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2006
• 资助国家: 英国
• 起止时间: 2006 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0500794%2F1
• 关键词: Development; validation; functional; cell; therapies

Involving neural tissue transplantation in the brain, as well as stem cells, human embryos and animal experiments, this research is high profile in the general as well as scientific news media. In addition to publication in peer reviewed journals, the results of the present project will be widely disseminated to the biomedical research community, to NHS and clinical professions, and to interested charities and the lay public, through lectures and seminars in the normal way as well as in media interviews when appropriate. The PIs already have extensive experience in public communication of research results. We strive to achieve the best balance between the competing demands of proper disclosure of publicly funded science, public education, promoting enthusiasm for science and support for the MRC and biomedical research, but without raising false or premature hopes for cures that remain distant. The credibility of the team is enhanced by the close collaboration of the two PIs, one a basic scientist and the other a clinical scientist, combining resources and expertise to develop a translational programme for novel cell-based treatments for crippling human neurodegenerative diseases, spanning basic cellular, molecular and behavioural science through to clinical delivery in patients.

这项研究涉及大脑中的神经组织移植，以及干细胞，人类胚胎和动物实验，在一般和科学新闻媒体中备受瞩目。除了在同行评审的期刊上发表外，本项目的结果还将通过正常方式的讲座和研讨会以及适当时的媒体采访，向生物医学研究界、NHS和临床专业人员以及感兴趣的慈善机构和非专业公众广泛传播。研究所所长在向公众宣传研究成果方面已有丰富的经验。我们努力在适当披露公共资助的科学，公众教育，促进对科学的热情和对MRC和生物医学研究的支持的相互竞争的需求之间实现最佳平衡，但不会对仍然遥远的治疗提出错误或过早的希望。该团队的可信度得到了两名PI的密切合作，其中一名是基础科学家，另一名是临床科学家，结合资源和专业知识，为基于细胞的新型治疗方法开发了一个转化计划，用于严重的人类神经退行性疾病，涵盖基础细胞，分子和行为科学，直到患者的临床交付。